Current therapeutic approaches for chronic maintenance treatment in asthma support the addition of a long-acting β-agonist (LABA) to an inhaled corticosteroid (ICS). Notably, substantial clinical evidence attests to a potential risk of asthma mortality associated with LABAs when prescribed as monotherapy without concomitant ICS or scheduled medical review.
Download PDF